MLTX · MoonLake Immunotherapeutics
The AI's read
MoonLake reported positive Week 16 topline Phase 3 IZAR-1 results for sonelokimab, meeting all primary and secondary endpoints with solid ACR and skin responses. Blinded safety matched prior data and dropout rates were low, so efficacy and tolerability look credible. The market did the opposite and pushed the stock down ~6.3% on the print. That drop looks more like skepticism or profit-taking than a fundamentals reversal given RSI ~62 and the stock still well below its 52-week high. We lean bullish: a clean Phase 3 topline plus $537M in cash reduces near-term dilution risk and keeps the program funded into mid-2028. Main constraints are timing and commercialization risk since the full 52-week readout is due 1H 2027 and payer/regulatory work still lies ahead.